-
1 Comment
Cyclopharm Limited is currently in a long term downtrend where the price is trading 34.4% below its 200 day moving average.
From a valuation standpoint, the stock is 94.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.3.
Cyclopharm Limited's total revenue rose by 17.6% to $9M since the same quarter in the previous year.
Its net income has dropped by 451.4% to $-394K since the same quarter in the previous year.
Finally, its free cash flow fell by 118.9% to $-3M since the same quarter in the previous year.
Based on the above factors, Cyclopharm Limited gets an overall score of 2/5.
| Industry | Medical Devices |
|---|---|
| Sector | Healthcare |
| ISIN | AU000000CYC5 |
| CurrencyCode | AUD |
| Exchange | AU |
| Beta | 0.73 |
|---|---|
| Target Price | 1.66 |
| Dividend Yield | 0.5% |
| PE Ratio | 0.0 |
| Market Cap | 184M |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CYC.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
